Finding the right connection can be the key in preventing and predicting devastating health events like a heart attack. Through its partnership with Zuellig Pharma Corporation, Amgen Philippines Inc aims to help improve awareness of cardiovascular diseases (CVD) with educational initiatives to achieve the goal of changing the way the disease is managed and prevented.
Dr. Lourdes Ella Santos, MD, Adult Cardiologist and Lipidologist shares important information last Sept 10,2019 at the Crowne Plaza.
Watch full video
In the Philippines, there are over 130,000 deaths related to Cardiovascular disease in 2016 CVD is a complex disease with many risk factors that affects how it develops. One such risk is dyslipidemia, which occurs when one has abnormal levels of lipids in the blood. Lipids, or fats, are essential in providing energy to the cells while cholesterol is vital in the production of hormones and bile acids for healthy digestion.
There are two kinds of cholesterol in the body: “Bad” cholesterol and ‘good” cholesterol. Elevated bad cholesterol, also known as low-density lipoprotein (LDL-C), in the blood increases a person’s risk of developing atherosclerotic plaque deposits which can block the arteries and lead to a heart attack or stroke. Lowering LDL-C also lowers a person’s chances of developing
The standard treatment for lowering LDL-C are statins, but there are cases when statins are not enough. Having access to new and innovative treatments in the management of dyslipidemia can make a difference for patients who are not able to achieve their lipid goals with statin alone.
With the patient at the heart of what we do, Amgen Philippines Inc. and Zuellig Pharma
Corporation are committed to improving the lives of patients struggling with dyslipidemia by helping them and their families to take the necessary action to prevent and manage their health risks.